drugset / Trial / NCT06365424

Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)

NCT06365424

Phase 2/3 Recruiting 117 enrolled Xijing Hospital of Digestive Diseases
RandomizedParallel-groupOpen-labelTreatment

Summary

An Open Label Long-Term Study to Evaluate the Safety and Effectiveness of Fenofibrate in Subjects with Primary Biliary Cholangitis (PBC)

Timeline

Start
2017-04-08
Primary completion
2027-04
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 200 mg
Subject Ursodeoxycholic Acid Small molecule 13 mg/kg
Subject Ursodeoxycholic Acid Small molecule 15 mg/kg